Foxp^3＋淋巴细胞在乳腺癌组织中的表达及临床意义

目的探讨Foxp^3＋淋巴细胞在人乳腺癌组织中的表达及其与其他临床病理因素的关系,并对其可能作用机制进行探讨。方法采用流式细胞术（FCM）检测30例乳腺癌患者肿瘤组织及癌旁正常组织中Foxp^3＋淋巴细胞百分率,并采用多元线性回归分析法统计分析肿瘤组织中Foxp^3＋淋巴细胞表达与患者临床病理学特征的相互关系;免疫组化法检测肿瘤组织及癌旁正常组织中浸润淋巴细胞中TGF-β和IL-10表达情况,并采用直线相关分析法统计分析其与Foxp^3＋淋巴细胞表达的相关性。结果肿瘤组织中Foxp^3＋淋巴细胞百分率明显高于癌旁正常组织（P〈0.05）,同时肿瘤组织中Foxp^3＋淋巴细胞百分率与临床分期、有无脉管瘤栓、腋淋巴结转移等临床病理因素有关（P〈0.05）。肿瘤组织浸润淋巴细胞的IL-10表达与肿瘤组织中Foxp^3＋淋巴细胞百分率正相关（P〈0.05）。结论Foxp3＋淋巴细胞与乳腺癌侵袭转移有关,其机制与其分泌IL-10抑制机体抗肿瘤免疫有关。Foxp^3＋淋巴细胞可作为乳腺癌预后判断的辅助指标,也有望成为乳腺癌临床治疗的新标靶。

Expression of Foxp3~+ lymphocytes in breast carcinoma tissues and their clinic significance

Objective To investigate the expression of Foxp3~+ lymphocytes in breast carcinoma tissues and their correlation with other pathological factors,and to investigate the mechanism of action of Treg cells.Methods The expression of Foxp3~+ lymphocytes in the breast cancer tissue and non-cancerous tissue was detected by flow cytometry (FCM) in 30 breast carcinoma patients, and its correlation with other pathological factors was statistically analyzed by multiple linear regression analysis.The expression of TGF-β and IL-10 in the lymphocytes infiltrated in breast cancer tissue and non-cancerous tissue was measured by immunohistochemistry, and their correlation with the expression of Foxp3~+ lymphocytes was statistically analyzed by linear correlation dependability analysis. Results There was significant difference in the expression of Foxp3~+ lymphocytes between the malignant and non-cancerous breast tissues(P<0.05),and it was positively correlated with the clinical stage,blood vessel invasion and the matter of axillary lymph node metastasis(P<0.05). The expression of IL-10 in the tumor infiltrating lymphocytes was positively correlated with the expression of Foxp3~+ lymphocytes(P<0.05).Conclusion The expression level of Foxp3~+ lymphocytes is correlated with invasion and metastasis of breast carcinoma, and the IL-10 secreted by Foxp3~+ lymphocytes may be involved in this effect.Foxp3~+ lymphocytes can be used as an assistant marker for prediction and new therpeutic target of breast cancer.